Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T W Kim

Showing results (211-220 of 240) with videos related to

Pageof 24
Sort By:
Nature Medicine|February 1, 1996
Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cellsD M Kovacs, H J Fausett, K J Page, et al.
Oncogene|October 20, 2009
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cellsG-Y Jang, J-H Jeon, S-Y Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionR Obermannová, E Van Cutsem, T Yoshino, et al.
British Journal of Cancer|February 18, 2011
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activityK-p Kim, G Jang, Y S Hong, et al.
British Journal of Cancer|October 15, 2009
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerC Yoo, J Y Hwang, J-E Kim, et al.
ESMO Open|June 16, 2023
Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysisJ Hyung, J Y Lee, J E Kim, et al.
Histopathology|August 31, 2007
Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumoursM H Ryu, Y K Kang, S J Jang, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?R D Peixoto, J M Loree, T A Miranda, et al.
Neoplasma|November 8, 2013
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cellsH J An, E K Choi, J S Kim, et al.
British Journal of Cancer|July 31, 2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerJ-L Lee, Y-K Kang, H J Kang, et al.
Pageof 24

Showing results (211-220 of 240) with videos related to

Sort By:
Pageof 24
Nature Medicine|February 1, 1996
Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cellsD M Kovacs, H J Fausett, K J Page, et al.
Oncogene|October 20, 2009
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cellsG-Y Jang, J-H Jeon, S-Y Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionR Obermannová, E Van Cutsem, T Yoshino, et al.
British Journal of Cancer|February 18, 2011
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activityK-p Kim, G Jang, Y S Hong, et al.
British Journal of Cancer|October 15, 2009
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerC Yoo, J Y Hwang, J-E Kim, et al.
ESMO Open|June 16, 2023
Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysisJ Hyung, J Y Lee, J E Kim, et al.
Histopathology|August 31, 2007
Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumoursM H Ryu, Y K Kang, S J Jang, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?R D Peixoto, J M Loree, T A Miranda, et al.
Neoplasma|November 8, 2013
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cellsH J An, E K Choi, J S Kim, et al.
British Journal of Cancer|July 31, 2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerJ-L Lee, Y-K Kang, H J Kang, et al.
Pageof 24